Information about species or isolates that are resistant or
have MICs near the proposed breakpoint is of particular interest and should be presented, for both evaluable and intent-to-treat populations.
When an antimicrobial is developed that is a combination
product, then a justification for the selected ratios or concentrations must be presented.